Nav: Home

Molecular tinkering doubles cancer drug's efficacy

August 04, 2015

DURHAM, N.C. -- Researchers have packaged a widely used cancer drug into nanoparticles, more than doubling its effectiveness at destroying tumors.

The drug paclitaxel has been used for decades to fight breast, ovarian, lung and other cancers. But its effectiveness has been limited by its small molecular size and insolubility in water -- properties that allow the body to clear the drug too quickly, reducing its accumulation in tumors.

Many molecular packaging systems have been developed to deliver the drug while counteracting these effects, with a protein-bound version of the drug called Abraxane currently the leading therapy.

But Ashutosh Chilkoti, professor and chair of the Department of Biomedical Engineering at Duke University, thought his team could do better.

By surrounding molecules of paclitaxel with self-assembling spheres composed of amino acids, the Duke team doubled tumor exposure to the drug compared to Abraxane while simultaneously reducing its effects on healthy tissue. This kept mice with tumors alive significantly longer and, in some cases, completely eradicated the tumors.

The results were published online in Nature Communications on August 4, 2015.

The big difference between Abraxane and the Duke approach is the types of molecular bonds that are formed. In Abraxane, the paclitaxel is physically surrounded by albumin, a common blood protein. In the new packaging system, multiple copies of the drug are chemically bonded to an amino acid polypeptide, forming a water-soluble nanoparticle with the drug hidden in its core.

These nanoparticles are highly soluble in blood and are the perfect size to penetrate and accumulate in tumors where they take advantage of a tumor's acidic environment.

"The chemical bonds holding the polypeptide cage together are stable in blood, but dissolve in a tumor's lower pH levels," said Jayanta Bhattacharyya, senior researcher in Chilkoti's lab and first author on the paper. "This delivers the drug directly to the tumor and helps prevent it from randomly absorbing into healthy tissue, reducing side effects."

To test their system, Chilkoti, Bhattacharyya and their colleagues used two groups of mice. The first group had human breast cancer growing in their own mammary glands. While none of the mice treated with Abraxane survived past 85 days, most of the mice treated with the new packaging system survived past 100 days.

A second group of mice had human prostate tumors growing under their skin. Similarly, while they did not survive past 60 days when treated with Abraxane, every single mouse treated with the new packaging system survived past 70 days, with some experiencing a complete cure.

As the mortality rates suggest, the Duke technology showed a higher concentration of paclitaxel in the tumors with more staying power than Abraxane, while simultaneously showing much lower levels throughout the rest of the mice's bodies.

"Clearly in the animal model there is a night and day difference, and if that translates to people it will be transformative for patients," said Neil Spector, an oncologist at Duke Medicine familiar with the work. "But it's not just the increase in clinical efficacy and outcomes that are exciting, it's also the improvement in targeting and reduction in toxicity, which is just icing on the cake. And since this platform could potentially be used for such a broad array of drugs, it could be a game-changer for cancer therapy."

In future work, Chilkoti and coworkers will begin applying the packaging system to other cancer drugs with the goal of developing a "one size fits all" technology to improve the effectiveness of many other cancer drugs.
-end-
This research was supported by the National Institutes of Health (R01 EB000188, R01 EB007205).

"A Paclitaxel-Loaded Recombinant Polypeptide Nanoparticle Outperforms Abraxane in Multiple Murine Cancer Models." Jayanta Bhattacharyya, Joseph J. Bellucci, Isaac Weitzhandler, Jonathan R. McDaniel, Ivan Spasojevic, Xinghai Li, Chao-Chieh Lin, Jen-Tsan Ashley Chi and Ashutosh Chilkoti. Nature Communications, 2015. DOI: 10.1038/ncomms8939

Duke University

Related Tumors Articles:

Directing nanoparticles straight to tumors
Modern anticancer therapies aim to attack tumor cells while sparing healthy tissue.
A solid vaccine for liquid tumors
Acute myeloid leukemia (AML) is a deadly blood cancer that kills most of its victims within five years.
Evolutionarily novel genes work in tumors
A team of scientists from Peter the Great St. Petersburg Polytechnic University studied the evolutionary ages of human genes and identified a new class of them expressed in tumors -- tumor specifically expressed, evolutionarily novel (TSEEN) genes.
Identification of all types of germ cells tumors
Germ cell tumors were considered very heterogeneous and diverse, until recently.
Laser light detects tumors
A team of researchers from Jena presents a groundbreaking new method for the rapid, gentle and reliable detection of tumors with laser light.
Better prognosticating for dogs with mammary tumors
For dogs with mammary tumors, deciding a course of treatment can depend on a variety of factors, some of which may seem to contradict one another.
The evolution of brain tumors
Scientists from the German Cancer Research Center found in a recent study that only three different genetic alterations drive the early development of malignant glioblastomas.
Why some brain tumors respond to immunotherapy
Fewer than 1 in 10 patients with glioblastoma -- the most common type of brain cancer -- respond to immunotherapy; a new study reveals how to detect patients who may respond.
Heating up cold tumors
A Ludwig Cancer Research study has uncovered a cellular mechanism by which melanomas that fail to respond to checkpoint blockade may be made susceptible to such immunotherapies.
Physics can show us the inside of tumors
A team of physicists from the CNRS and Université Claude Bernard Lyon 1 has demonstrated the potential, for oncology, of an imaging technique based only on the physical properties of tumors.
More Tumors News and Tumors Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Clint Smith
The killing of George Floyd by a police officer has sparked massive protests nationwide. This hour, writer and scholar Clint Smith reflects on this moment, through conversation, letters, and poetry.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.